The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Journal
Haematologica
Journal Volume
111
Journal Issue
1
Start Page
286
End Page
299
ISSN
1592-8721
Date Issued
2026-01-01
Author(s)
Mizuno, Shohei
Gras, Luuk
Baaij, Laurien G A
Koster, Linda
D'Souza, Anita
Hari, Parameswaran N
Estrada-Merly, Noel
Saber, Wael
Cowan, Andrew J
Iida, Minako
Okamoto, Shinichiro
Takamatsu, Hiroyuki
Kawamura, Koji
Kodera, Yoshihisa
Hamad, Nada
Liam, Christopher
Ho, Kim Wah
Goh, Ai Sim
Keat, Tan Sui
Elhaddad, Alaa M
Bazarbachi, Ali
Chaudhry, Brig Qamar Un N
Alfar, Rozan
Bekadja, Mohamed Amine
Benakli, Malek
Ortiz, Cristobal Augusto Frutos
Riva, Eloisa
Verburgh, Estelle
Galeano, Sebastian
Bass, Francisca
Mian, Hira
McCurdy, Arleigh
Wang, Feng Rong
Neumann, Daniel
Koh, Mickey Boon Chai
Snowden, John A
Schönland, Stefan
McLornan, Donal P
Hayden, Patrick J
Balari, Anna Maria Sureda
Greinix, Hildegard T
Aljurf, Mahmoud
Atsuta, Yoshiko
Rondelli, Damiano
Niederwieser, Dietger W
Garderet, Laurent
Abstract
Despite the availability of novel agents, autologous hematopoietic cell transplantation (auto-HCT) remains the standard of care in newly diagnosed multiple myeloma (MM) patients. The impact of age on overall survival (OS), progression-free survival (PFS), relapse incidence, non-relapse mortality (NRM), and excess mortality (taking account of general population mortality) was investigated using information on 61,797 MM patients transplanted between 2013 and 2017. The median age at auto-HCT was 60.8 (range, 18.1-83.2) years of whom 2.0% were 18-39 years, 68.9% 40-64 years, 21.8% 65-69 years, 6.5% 70-74 years, and 0.8% ≥75 years of age, respectively. The corresponding OS probabilities at 3 years were 85.9%, 82.8%, 81.1%, 78.4%, and 74.8%, respectively (P<0.001). Excess mortality cumulative incidences were 13.1%, 15.0%, 14.6%, 15.0%, and 14.1% at 3 years, respectively (P=0.67). In multivariable analyses, older age was a significant risk factor for OS, PFS, and NRM but not for excess mortality or relapse risk. Our results indicate that advanced age alone should not preclude the use of auto- HCT in patients with MM.
Type
journal article